NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2071220108

Registered date:17/02/2023

A Thorough QT/QTc Study of TAS5315 in Healthy Adult Subjects

Basic Information

Recruitment status Complete
Health condition(s) or Problem(s) studiedhealthy adult males and females
Date of first enrollment15/03/2023
Target sample size48
Countries of recruitment
Study typeInterventional
Intervention(s)Orally administration of TAS5315 (4mg or 8mg), placebo and Moxifloxacin

Outcome(s)

Primary OutcomeDifference between TAS5315 and placebo in change from baseline in QT-interval corrected by heart rate using Fridericia corrections [QTcF]
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximum< 40age old
GenderBoth
Include criteria1) Aged 18 or older and younger than 40 years at the time of consent 2) Weigh at least 45.0 kg at the time of screening tests with a body mass index (BMI, weight [kg]/[height {m}]2) ranging from 18.0 to < 25.0 kg/m2 3) Vital signs obtained in screening tests within the following ranges a Systolic blood pressure (in supine position), 90 to 139 mmHg b Diastolic blood pressure (in supine position), 40 to 89 mmHg c Body temperature ranging from 35.0 to 37.4 4) Judged to be healthy by the investigator based on the examination findings (subjective symptoms and objective findings), blood pressure, pulse rate, body temperature, 12-lead ECG, and laboratory tests (hematology test, biochemistry test, and urinalysis) at the time of screening tests
Exclude criteria1) Had any concurrent disease (including symptoms and signs; however, diseases that do not affect evaluations in the study such as asymptomatic pollinosis and wart are excluded) 2) Had a history of torsade de pointes, unconsciousness of uncertain cause and convulsion of uncertain cause 3) Using pacemaker or implantable cardioverter defibrillator, or cardiac resynchronization device 4) Judged by the investigator to be ineligible as a participant of the clinical study based on the 12-lead ECG at the time of screening test (QT-interval corrected by Fridericia corrections [QTcF] is 450 msec or more, etc.)

Related Information

Contact

Public contact
Name Kotaro Suto
Address 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo Tokyo Japan 101-8444
Telephone +81-3-3293-2455
E-mail th-tas5315_clinical@taiho.co.jp
Affiliation Taiho Pharmaceutical Co., Ltd.
Scientific contact
Name Ali Nasermoaddeli
Address 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo Tokyo Japan 101-8444
Telephone +81-3-3293-2455
E-mail th-tas5315_clinical@taiho.co.jp
Affiliation Taiho Pharmaceutical Co., Ltd.